- Home
- PRFX vs NAOV Comparison
PRFX vs NAOV Comparison
Compare PRFX & NAOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- NAOV
- Stock Information
- Founded
- PRFX 2007
- NAOV 2003
- Country
- PRFX Israel
- NAOV United States
- Employees
- PRFX N/A
- NAOV N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- NAOV Industrial Specialties
- Sector
- PRFX Health Care
- NAOV Health Care
- Exchange
- PRFX Nasdaq
- NAOV Nasdaq
- Market Cap
- PRFX 2.8M
- NAOV 2.4M
- IPO Year
- PRFX 2020
- NAOV N/A
- Fundamental
- Price
- PRFX $1.33
- NAOV $0.80
- Analyst Decision
- PRFX Hold
- NAOV
- Analyst Count
- PRFX 1
- NAOV 0
- Target Price
- PRFX N/A
- NAOV N/A
- AVG Volume (30 Days)
- PRFX 138.2K
- NAOV 871.7K
- Earning Date
- PRFX 08-15-2025
- NAOV 08-18-2025
- Dividend Yield
- PRFX N/A
- NAOV N/A
- EPS Growth
- PRFX N/A
- NAOV N/A
- EPS
- PRFX N/A
- NAOV N/A
- Revenue
- PRFX N/A
- NAOV $2,662,000.00
- Revenue This Year
- PRFX N/A
- NAOV N/A
- Revenue Next Year
- PRFX N/A
- NAOV N/A
- P/E Ratio
- PRFX N/A
- NAOV N/A
- Revenue Growth
- PRFX N/A
- NAOV N/A
- 52 Week Low
- PRFX $1.25
- NAOV $0.67
- 52 Week High
- PRFX $16.63
- NAOV $16.25
- Technical
- Relative Strength Index (RSI)
- PRFX 35.46
- NAOV 35.72
- Support Level
- PRFX $1.25
- NAOV $0.80
- Resistance Level
- PRFX $1.55
- NAOV $0.88
- Average True Range (ATR)
- PRFX 0.07
- NAOV 0.07
- MACD
- PRFX -0.00
- NAOV 0.01
- Stochastic Oscillator
- PRFX 26.67
- NAOV 31.61
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About NAOV NanoVibronix Inc.
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.